GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (FRA:XSQ) » Definitions » Capex-to-Revenue

SQI Diagnostics (FRA:XSQ) Capex-to-Revenue : 0.00 (As of Mar. 2023)


View and export this data going back to 2010. Start your Free Trial

What is SQI Diagnostics Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

SQI Diagnostics's Capital Expenditure for the three months ended in Mar. 2023 was €0.00 Mil. Its Revenue for the three months ended in Mar. 2023 was €0.17 Mil.

Hence, SQI Diagnostics's Capex-to-Revenue for the three months ended in Mar. 2023 was 0.00.


SQI Diagnostics Capex-to-Revenue Historical Data

The historical data trend for SQI Diagnostics's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics Capex-to-Revenue Chart

SQI Diagnostics Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.11 0.18 1.78 0.15

SQI Diagnostics Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.21 0.01 0.10 0.61 -

Competitive Comparison of SQI Diagnostics's Capex-to-Revenue

For the Diagnostics & Research subindustry, SQI Diagnostics's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SQI Diagnostics's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, SQI Diagnostics's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where SQI Diagnostics's Capex-to-Revenue falls into.



SQI Diagnostics Capex-to-Revenue Calculation

SQI Diagnostics's Capex-to-Revenue for the fiscal year that ended in Sep. 2022 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.916) / 6.135
=0.15

SQI Diagnostics's Capex-to-Revenue for the quarter that ended in Mar. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 0.173
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SQI Diagnostics  (FRA:XSQ) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


SQI Diagnostics Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


SQI Diagnostics (FRA:XSQ) Business Description

Traded in Other Exchanges
N/A
Address
36 Meteor Drive, Toronto, ON, CAN, M9W 1A4
SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.

SQI Diagnostics (FRA:XSQ) Headlines

No Headlines